Tag : DIABETES
Despite being an established biomarker for heart failure, the utility of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in identifying broader complications, such as cardiorenal dysfunction, has remained underexplored. This knowledge gap, particularly within Asian populations, has limited the ability of clinicians to stratify risk and intervene early in patients at the highest risk of adverse outcomes. A retrospective cohort study utilizing the Hong Kong Diabetes Biobank (HKDB), led by researchers from the Department of Medicine and Therapeutics, The Chinese University of Hong Kong (CUHK) found NT-proBNP as a reliable biomarker for predicting cardiovascular and renal complications in patients with type 2 diabetes (T2DM).
Severe hypoglycemia (SH), a dangerously low blood glucose level (<70mg/dL) that requires assistance from a third party, is a major concern for older adults with diabetes. Beyond the immediate medical emergency, SH is associated with a range of serious consequences, including prolonged hospitalizations, higher healthcare expenditures, increased risks of cardiovascular disease, falls, cognitive decline and elevated mortality. In response to this clinical challenge, researchers from CU Medicine developed a novel machine learning (ML) model capable of predicting the one-year risk of SH requiring hospitalization in older adults with diabetes. This predictive tool has the potential to enable targeted interventions and improve diabetes management outcomes in this high-risk population.
According to the American Diabetes Association (ADA)/ European Association for the Study of Diabetes (EASD) guideline, a patient-centered approach to type 2 diabetes (T2D) management should be adopted with the goal of not only preventing complications but also optimizing patients’ quality of life.1 To achieve these goals, factors that affect health-related quality of life (HRQoL) such as social determinants of health, psychosocial well-being, and health behaviors are key considerations in glycemic management strategies for patients with T2D.1 At the EASD Annual Meeting 2023, Professor Chan, Chung-Ngor Juliana from the Department of Medicine and Therapeutics, The Chinese University of Hong Kong presented the results of a cross-sectional analysis of HRQoL in patients with T2D treated with oral glucose-lowering drugs (OGLDs) who were enrolled in the Joint Asia Diabetes Evaluation (JADE) Register. In a subsequent interview with Omnihealth Practice, Prof. Chan shared further insights on the application of the JADE® Program, shedding light on the dynamics between glycemic management strategies and patients’ HRQoL.
